Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
Go back to Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma| Rider Explorations, Inc. (NASDAQ: REPL) | Delayed: 15.04 -0.25 (1.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.29 | 52 Week High | $1.45 | |||
| Open | $15.22 | 52 Week Low | $0.50 | |||
| Day High | $15.33 | P/E | N/A | |||
| Day Low | $14.80 | EPS | $0.00 | |||
| Volume | 910,230 | |||||
